Quantitative structure–activity relationships of 1,3,4-thiadiazol-2(3H)-ones and 1,3,4-oxadiazol-2(3H)-ones as human protoporphyrinogen oxidase inhibitors

Add time:09/06/2019    Source:sciencedirect.com

Protoporphyrinogen oxidase (Protox, EC 1.3.3.4) has attracted great interest during the last decades due to its unique biochemical characteristics and biomedical significance. As a continuation of our research work on the development of new PPO inhibitors, 23 new 1,3,4-thiadiazol-2(3H)-ones bearing benzothiazole substructure were designed and synthesized. The in vitro assay indicated that the newly synthesized compounds 1a–w displayed good inhibition activity against human PPO (hPPO) with Ki values ranging from 0.04 μM to 245 μM. To the knowledge, compound 1a, O-ethyl S-(5-(5-(tert-butyl)-2-oxo-1,3,4-thiadiazol-3(2H)-yl)-6-fluorobenzothiazol-2-yl)carbonothioate, with the Ki value of 40 nM, is so far known as the most potent inhibitor against hPPO. Based on the molecular docking and modified molecular mechanics/Poisson–Boltzmann surface area (MM-PBSA) calculations, the quantitative structure–activity relationships of 1,3,4-thiadiazol-2(3H)-ones and 1,3,4-oxadiazol-2(3H)-one derivatives were established with excellent correlation relationships (r2 = 0.81) between the calculated and experimental binding free energies. Some important insights were also concluded for guiding the future rational design of new hPPO inhibitors with improved potency.

We also recommend Trading Suppliers and Manufacturers of N-(5-BUTYL-[1,3,4]THIADIAZOL-2-YL)-2-CHLORO-ACETAMIDE (cas 15777-44-3). Pls Click Website Link as below: cas 15777-44-3 suppliers

Prev:Oral toxicity of tebuthiuron (1-(5-tert-butyl-1,3,4-thiadiazol-2-yl-2-y)-1,3-dimethylurea) in experimental animalsToxicitéorale du tébuthiuron (1-(5-tert-butyl-1,3,4-thiadiazol-2-yl)-1,3-diméthylurée) chez les animaux expérimentauxOrale toxizität von tebuthiuron (1-(5-tert-Butyl-1,3,4-thiadiazol-2-yl)-1,3-dimethylurea) in Versuchstieren
Next:Original articleSynthesis and antileishmanial activity of novel 5-(5-nitrofuran-2-y1)-1,3,4-thiadiazoles with piperazinyl-linked benzamidine substituents)